Utility of the Repeatable Batter for the Assessment of Neuropsychological Status (RBANS) as Endpoint in AD Trials

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a brief neurocognitive battery that is commonly used in clinical settings to detect and track early symptomatic Alzheimer’s disease (AD) and other neurodegenerative conditions that involve neurocognitive compromise. The RBANS has also been used as an endpoint in trials involving presymptomatic and early symptomatic AD. As the RBANS generates scores that are scaled to population norms, it theoretically may be subject to floor effects in more impaired populations. The present study examined screening RBANS data from several multinational clinical trials of presymptomatic and early symptomatic AD as a function of CDR sum of box (CDR‐SB) stages.